Clinical Trials Sponsored by Mundipharma (China) Pharmaceutical Co. Ltd

Total 4136 results

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects

Multiple Myeloma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma.

Severe Asthma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Phase I Clinical Trial of TQB3915 Tablets in Subjects With Advanced Malignant Solid Tumors

Advanced Malignant Tumor

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail

HR-positive,HER2-negative in Advanced Breast Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).

Advanced Non-squamous Non-small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

To Evaluate the Pharmacokinetic Effects of TQD3606 for Injection in Healthy Adult Subjects

Infections

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Phase II Clinical Trial of TQC3721 Suspension for Inhalation

Chronic Obstructive Pulmonary Disease (COPD)

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advanced Malignant Tumors

Advanced Malignant Tumors

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of TQ-B3234 in Patients With Type I Neurofibromatosis

Type I Neurofibromatosis

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx

Unresectable Metastatic Colorectal Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Trial of TQC3721 Suspension for Inhalation

Chronic Obstructive Pulmonary Disease

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis

Moderate and High Risk Myelofibrosis

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQB3820 in Patients With Hematological Malignancies

Hematological Malignancies

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Phase I Clinical Trial of TQC2731 Injection

Asthma Severe Persistent Controlled

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer

Advanced Lung Carcinoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets

Metastatic Castration-resistant Prostate Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Study of TQB2450 Injection in Subjects With PD-L1 Positive Recurrent or Metastatic Cervical Cancer

Recurrent or Metastatic Cervical Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL）

Diffuse Large B-cell Lymphoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer

Advanced Endometrial Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets

Advanced Solid Tumor or Hematologic Tumor

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma

Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma (HCC)

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)

Stage III Non-small-cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQ-B3525 on Tolerance and Pharmacokinetics

Relapsed or Refractory Lymphoma or Advanced Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients

Myelofibrosis

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Clinical Trial of Safety and Tolerance of TQH3821 Tablets in Adult Healthy Subjects

Rheumatoid Arthritis

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer

HR-positive, HER2-negative Breast Neoplasms

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Withdrawn

A Clinical Trial of TQB3015 Tablets in Patients With Advanced Malignant Cancer

Advanced Malignant Neoplasm

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.

HER2-positive Breast Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

To Evaluate the Effect of Food on the Pharmacokinetics of TQ05105 Tablets in Healthy Adult Subjects

Myelofibrosis

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

Clinical Trial of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced Cancers

Advanced Cancers

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

A Clinical Study of TQB3823 in Patients With Advanced Malignant Tumor

Advanced Solid Tumor

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD)

Glucocorticoid-Refractory aGVHD

China
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.

Enrolling by invitation

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of FHND5071 as a Single Agent in Adult Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Bioequivalence Study of Dasatinib Tablet

Leukemia, Myelogenous, Chronic

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Pharmacokinetic Study of TQB3101 in Chinese Healthy Subjects

Pharmacokinetic Study

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Human Bioequivalence Test of Liraglutide Injection

Type 2 Diabetes

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer

Advanced Biliary Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia.

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2618 Injection in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection

Indolent B-Cell Non-Hodgkin's Lymphomas

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis（HLH）

Hemophagocytic Lymphohistiocytosis

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor

Advanced Malignant Tumor

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes

Type 2 Diabetes

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets

Non-small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.

HER2-positive Metastatic Breast Cancer

China

3

Subscribe